- Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration2022 | 1. lékařská fakulta
- Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry2020 | 1. lékařská fakulta
- Jak ovlivňuje biologická léčba práceschopnost u nemocných s axiální spondyloartritidou - výsledky z Českého národního registru ATTRA2021 | 1. lékařská fakulta
- Spondyloartritidy2020 | 1. lékařská fakulta, 3. lékařská fakulta
- 19 Psoriáza2023 | 3. lékařská fakulta
- Přehled biomarkerů a jejich vztah k axiálním spondyloartritidám asociovaným s idiopatickými střevními záněty2021 | 1. lékařská fakulta
- Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis2017 | 1. lékařská fakulta
- Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching2023 | 1. lékařská fakulta
- Treatment response and drug retention rates in 24 195 biologic-naive patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration2019 | 1. lékařská fakulta
- Depression and anxiety in individuals with axial spondyloarthritis and nonspecific low back pain who are interested in non-pharmacological therapy options: Cross-sectional study2022 | 1. lékařská fakulta, Fakulta tělesné výchovy a sportu
- Metabolites of type I, II, III, and IV collagen may serve as markers of disease activity in axial spondyloarthritis2019 | 1. lékařská fakulta
- Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA2022 | 1. lékařská fakulta, 2. lékařská fakulta
- Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis2019 | 1. lékařská fakulta
- A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis2021 | 1. lékařská fakulta
- Circulating miR-145 as a Marker of Therapeutic Response to Anti-TNF Therapy in Patients With Ankylosing Spondylitis2021 | 1. lékařská fakulta, Fakulta tělesné výchovy a sportu
- Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis2020 | 1. lékařská fakulta
- The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis2022 | 1. lékařská fakulta
- 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial2020 | 1. lékařská fakulta
